CN104958298A - 阿片样受体拮抗剂用于胃肠道疾病的用途 - Google Patents

阿片样受体拮抗剂用于胃肠道疾病的用途 Download PDF

Info

Publication number
CN104958298A
CN104958298A CN201510256187.6A CN201510256187A CN104958298A CN 104958298 A CN104958298 A CN 104958298A CN 201510256187 A CN201510256187 A CN 201510256187A CN 104958298 A CN104958298 A CN 104958298A
Authority
CN
China
Prior art keywords
compound
opioid
treatment
dose
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510256187.6A
Other languages
English (en)
Chinese (zh)
Inventor
R.M.伍德沃德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104958298(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of CN104958298A publication Critical patent/CN104958298A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201510256187.6A 2009-09-18 2010-09-17 阿片样受体拮抗剂用于胃肠道疾病的用途 Pending CN104958298A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24361609P 2009-09-18 2009-09-18
US61/243,616 2009-09-18
CN2010800522092A CN102695508A (zh) 2009-09-18 2010-09-17 阿片样受体拮抗剂用于胃肠道疾病的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800522092A Division CN102695508A (zh) 2009-09-18 2010-09-17 阿片样受体拮抗剂用于胃肠道疾病的用途

Publications (1)

Publication Number Publication Date
CN104958298A true CN104958298A (zh) 2015-10-07

Family

ID=43216894

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510256187.6A Pending CN104958298A (zh) 2009-09-18 2010-09-17 阿片样受体拮抗剂用于胃肠道疾病的用途
CN2010800522092A Pending CN102695508A (zh) 2009-09-18 2010-09-17 阿片样受体拮抗剂用于胃肠道疾病的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800522092A Pending CN102695508A (zh) 2009-09-18 2010-09-17 阿片样受体拮抗剂用于胃肠道疾病的用途

Country Status (19)

Country Link
US (1) US20110071163A1 (https=)
EP (1) EP2477627B1 (https=)
JP (1) JP5797655B2 (https=)
KR (1) KR20120092592A (https=)
CN (2) CN104958298A (https=)
AU (1) AU2010295464B2 (https=)
BR (1) BR112012006069A8 (https=)
CA (1) CA2774021A1 (https=)
CL (1) CL2012000676A1 (https=)
CO (1) CO6531453A2 (https=)
HK (1) HK1210959A1 (https=)
IL (1) IL218679A0 (https=)
MX (1) MX342548B (https=)
NZ (1) NZ598783A (https=)
PE (1) PE20120991A1 (https=)
RU (1) RU2561873C2 (https=)
TW (1) TW201118084A (https=)
WO (1) WO2011035142A1 (https=)
ZA (1) ZA201201954B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014102571A1 (en) * 2012-12-28 2014-07-03 Instytut Medycyny Doswiadczalnej I Klinicznej Im. Miroslawa Mossakowskiego Polskiej Akademii Nauk Peptidomimetics and their application
TN2018000355A1 (en) 2016-05-20 2020-06-15 Esteve Pharmaceuticals Sa Tetrahydropyran and thiopyran derivatives having multimodal activity against pain.
CN106117190B (zh) * 2016-06-21 2019-03-29 山东川成医药股份有限公司 一种倍福普兰的合成方法
CN113573711A (zh) 2019-01-04 2021-10-29 伊瑟治疗公司 治疗药物或酒精依赖性的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1681498A (zh) * 2002-09-19 2005-10-12 伊莱利利公司 作为阿片受体拮抗剂的二芳基醚

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191771A (en) * 1974-09-06 1980-03-04 Eli Lilly And Company Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5319087A (en) * 1987-04-16 1994-06-07 Eli Lilly And Company Piperidine opioid antagonists
US5064834A (en) * 1987-04-16 1991-11-12 Eli Lilly And Company Piperidine opioid antagonists
US4992450A (en) * 1987-04-16 1991-02-12 Eli Lilly And Company Piperidine opioid antagonists
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP0759303B1 (en) 1994-04-22 2002-10-16 Yamanouchi Pharmaceutical Co. Ltd. Colon-specific drug release system
US5378448A (en) * 1994-06-07 1995-01-03 Lin; Hsing K. Process for removing selenium from sulfur
TW490465B (en) * 1994-11-24 2002-06-11 Janssen Pharmaceutica Nv Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
EP0827746B1 (en) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
JP5068401B2 (ja) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Ｈｐｍｃカプセルを使用する腸及び結腸への送達
US6436959B1 (en) * 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
BRPI0014869B8 (pt) * 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
AU776567B2 (en) * 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
EP1575596B1 (en) * 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
ATE406360T1 (de) * 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
CA2549009A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
ES2390459T3 (es) * 2003-12-22 2012-11-13 Eli Lilly And Company Antagonistas de receptores de opioides
ATE399164T1 (de) * 2004-03-12 2008-07-15 Lilly Co Eli Antagonisten des opioidrezeptors
DE602005022572D1 (de) * 2004-03-12 2010-09-09 Lilly Co Eli Antagonisten des opioidrezeptors
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
MX2008009650A (es) * 2006-01-24 2008-11-06 R Tech Ueno Ltd Formulacion de capsula de gelatina suave.
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
EP2214672B1 (en) * 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
RU2482107C2 (ru) * 2007-12-11 2013-05-20 Тереванс, Инк. Производные 3-карбоксипропил-аминотетралина и родственные соединения в качестве антагонистов mu-опиоидного рецептора
JP5650657B2 (ja) * 2008-12-10 2015-01-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ３−カルボキシプロピル−アミノテトラリン化合物の結晶形態
TR201908514T4 (tr) * 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1681498A (zh) * 2002-09-19 2005-10-12 伊莱利利公司 作为阿片受体拮抗剂的二芳基醚
US20060217372A1 (en) * 2002-09-19 2006-09-28 Maria-Jesus Blanco-Pillado Diaryl ethers as opioid receptor antagonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JILL D FRIEDMAN,ET AL.: "Opioid Antagonists in the Treatment of Opioid-Induced Constipation and Pruritus", 《THE ANNALS OF PHARMACOTHERAPY》 *

Also Published As

Publication number Publication date
ZA201201954B (en) 2012-11-28
JP2013505260A (ja) 2013-02-14
NZ598783A (en) 2013-07-26
MX342548B (es) 2016-10-04
EP2477627B1 (en) 2018-08-15
EP2477627A1 (en) 2012-07-25
AU2010295464A1 (en) 2012-04-12
PE20120991A1 (es) 2012-08-01
BR112012006069A8 (pt) 2017-10-10
IL218679A0 (en) 2012-05-31
WO2011035142A1 (en) 2011-03-24
MX2012003310A (es) 2012-07-17
JP5797655B2 (ja) 2015-10-21
CO6531453A2 (es) 2012-09-28
AU2010295464B2 (en) 2015-11-26
CN102695508A (zh) 2012-09-26
TW201118084A (en) 2011-06-01
HK1210959A1 (en) 2016-05-13
RU2012115450A (ru) 2013-10-27
CL2012000676A1 (es) 2012-10-19
KR20120092592A (ko) 2012-08-21
CA2774021A1 (en) 2011-03-24
RU2561873C2 (ru) 2015-09-10
BR112012006069A2 (pt) 2016-03-29
US20110071163A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
Pascoe Opioid analgesics
Donnelly et al. Morphine in cancer pain management: a practical guide
ES2245461T3 (es) Metodo para aliviar el dolor mediante la combinacion de tramadol con un antagonista de nmda.
JP5714910B2 (ja) 薬学的組成物
ES2635733T3 (es) Uso de antagonistas opioideos para tratar la retención urinaria
CN102014907A (zh) 外周作用阿片拮抗剂的口服给药
WO2007120485A2 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
AU782523B2 (en) Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
KR101971412B1 (ko) 정맥 내 투여용 이부프로펜의 투여
CN104958298A (zh) 阿片样受体拮抗剂用于胃肠道疾病的用途
WO2008150324A1 (en) Subanalgesic doses of drug combinations
JP2006124380A (ja) 医薬組成物
Walsh et al. Buprenorphine pharmacodynamics and pharmacokinetics
JP4614638B2 (ja) 鎮痛剤組成物
WO2015191686A1 (en) Methods of administering methylnaltrexone
US20250345324A1 (en) Combination formulations of naloxone and atipamezole
US20240325379A1 (en) Low-dose naltrexol and uses thereof
Little Peripherally restricted opioid analgesics
HK40111880A (zh) 低剂量纳曲醇和其用途
Mampullinhalil Comparison of Intravenous Patient Controlled Analgesia Using Morphine+ IV Paracetamol with Intramuscular Bolus Doses of Pethidine+ IV Paracetamol for Post Operative Analgesic Efficacy in Patients Undergoing Hysterectomy
Sandhiya Alvimopan: A novel peripheral opioid receptor antagonist
Naughton Morphine in cancer pain management: a practical guide
CA2811285A1 (en) Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160120

Address after: new jersey

Applicant after: Schering Corporation

Address before: Massachusetts, USA

Applicant before: Adolor Corp.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1210959

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20151007

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1210959

Country of ref document: HK